BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bunchorntavakul C, Chavalitdhamrong D, Tanwandee T. Hepatitis C genotype 6: A concise review and response-guided therapy proposal. World J Hepatol 2013; 5(9): 496-504 [PMID: 24073301 DOI: 10.4254/wjh.v5.i9.496]
URL: https://www.wjgnet.com/1948-5182/full/v5/i9/496.htm
Number Citing Articles
1
Seung Kak Shin, Soo Yong Park, Young Kul Jung, Eui Joo Kim, Heon Nam Lee, Jong Joon Lee, Oh Sang Kwon, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim. Prevalence, Risk Factors and Clinical Characteristics in Patients with Genotype 6 Chronic Hepatitis C: A Single Institute ExperienceThe Korean Journal of Gastroenterology 2015; 65(2): 105 doi: 10.4166/kjg.2015.65.2.105
2
Mei-Hsuan Lee, Tiffany I Hsiao, Shreenidhi R Subramaniam, An K Le, Vinh D Vu, Huy N Trinh, Jian Zhang, Mingjuan Jin, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Mindie H Nguyen. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver CirrhosisAmerican Journal of Gastroenterology 2017; 112(7): 1111 doi: 10.1038/ajg.2017.123
3
Phuong Nguyen Thi Thu, Mai Ngo Thi Quynh, Linh Pham Van, Hung Nguyen Van, Hoi Nguyen Thanh, Fu-Ming Tsai. Determination of Risk Factors Associated with the Failure of 12 Weeks of Direct-Acting Antiviral Therapy in Patients with Hepatitis C: A Prospective StudyBioMed Research International 2022; 2022: 1 doi: 10.1155/2022/6054677
4
Kok-Siong Poon, Julian Wei-Tze Tang, Evelyn Siew- Chuan Koay. Bioinformatics Tools for Detection and Clinical Interpretation of Genomic Variations2019;  doi: 10.5772/intechopen.84577
5
V. Saxena, M. M. Manos, H. S. Yee, L. Catalli, E. Wayne, R. C. Murphy, V. A. Shvachko, M. P. Pauly, J. Chua, A. Monto, N. A. Terrault. Telaprevir or boceprevir triple therapy in patients with chronic hepatitis C and varying severity of cirrhosisAlimentary Pharmacology & Therapeutics 2014; 39(10): 1213 doi: 10.1111/apt.12718
6
Xiwei Wang, Fen Liu, Fang Wei, Hong Ren, Huaidong Hu, Wenzhe Ho. Efficacy and Safety of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 6: A Meta-AnalysisPLoS ONE 2014; 9(6): e100128 doi: 10.1371/journal.pone.0100128
7
Aung H. Bwa, Gayatri Nangia, Si T.S. Win, Soe T. Maung, Khin A.W. Han, Su S. Htar, Lei Y. Wine, Wint W. Ko, Moe P. Oo, Naomi K.T. Hlaing, Julia Palecki, Bao L. Loza, Khin M. Win, Rajender Reddy. Strategy and Efficacy of Generic and Pan-genotypic Sofosbuvir/Velpatasvir in Chronic Hepatitis C Virus: A Myanmar ExperienceJournal of Clinical and Experimental Hepatology 2019; 9(3): 283 doi: 10.1016/j.jceh.2018.12.001
8
Isaac Thom Shawa. Hepatitis B and C2020;  doi: 10.5772/intechopen.82772
9
Nattiya Kapol, Surasit Lochid-amnuay, Yot Teerawattananon. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0506-4
10
Filippo Ansaldi, Andrea Orsi, Laura Sticchi, Bianca Bruzzone, Giancarlo Icardi. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapyWorld Journal of Gastroenterology 2014; 20(29): 9633-9652 doi: 10.3748/wjg.v20.i29.9633
11
Joseph Mwangi, Zipporah Nganga, Solomon Mpoke, Raphael Lihana, Joyceline Kinyua, Nancy Lagat, Joseph Muriuki, Rency Lel, Sheila Kageha, Saida Osman, Hiroshi Ichimura. Hepatitis C virus genotypes in KenyaArchives of Virology 2016; 161(1): 95 doi: 10.1007/s00705-015-2623-8
12
Vasilios Papastergiou, Stylianos Karatapanis. Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6World Journal of Clinical Cases 2015; 3(3): 210-220 doi: 10.12998/wjcc.v3.i3.210
13
Chun‐Han Cheng, Huan‐Lin Chen, I‐Tsung Lin, Chia‐Hsien Wu, Yuan‐Kai Lee, Ming‐Wun Wong, Ming‐Jong Bair. The genotype distribution of hepatitis C in southeastern Taiwan: Clinical characteristics, racial difference, and therapeutic responseThe Kaohsiung Journal of Medical Sciences 2015; 31(11): 597 doi: 10.1016/j.kjms.2015.09.006
14
Chalermrat Bunchorntavakul, K. Rajender Reddy. Liver Disorders2017; : 143 doi: 10.1007/978-3-319-30103-7_11
15
Chengguang Hu, Guosheng Yuan, Junwei Liu, Huaping Huang, Yanyu Ren, Yinping Li, Xuefu Chen, Wei Li, Tao Wu, Hong Deng, Yanzhong Peng, Yong-Yuan Zhang, Yuanping Zhou. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in ChinaCanadian Journal of Gastroenterology and Hepatology 2018; 2018: 1 doi: 10.1155/2018/3908767
16
Winifred Nyinoh Iveren. Genotypic variation, demographic characteristics and risk factors of hepatitis C virus in ScotlandJournal of Public Health and Epidemiology 2018; 10(7): 241 doi: 10.5897/JPHE2018.1031
17
Jyh-Jou Chen, Yen-Cheng Chiu, Pei-Lun Lee, Hung-Da Tung, Hung-Chih Chiu, Shih-Chieh Chien, Pin-Nan Cheng. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis CJournal of the Formosan Medical Association 2022; 121(11): 2265 doi: 10.1016/j.jfma.2022.04.020
18
Pham Thi Thu Thuy, Chalermrat Bunchorntavakul, Ho Tan Dat, Julia Palecki, K Rajender Reddy. Sofosbuvir-Ledipasvir with or without Ribavirin for Chronic Hepatitis C Genotype-1 and 6: Real-World Experience in VietnamAntiviral Therapy 2018; 23(5): 415 doi: 10.3851/IMP3217
19
Panita Mettikanont, Chalermrat Bunchorntavakul, K. Rajender Reddy. Systematic review: epidemiology and response to direct‐acting antiviral therapy in genotype 6 chronic hepatitis C virus infectionAlimentary Pharmacology & Therapeutics 2019; 49(5): 492 doi: 10.1111/apt.15100
20
Hsin-Yun Sun, Chien-Yu Cheng, Chi-Ying Lin, Chia-Jui Yang, Nan-Yao Lee, Bo-Huang Liou, Hung-Jen Tang, Yuang-Meng Liu, Chun-Yuan Lee, Tun-Chieh Chen, Yi-Chia Huang, Yuan-Ti Lee, Ming-Jui Tsai, Po-Liang Lu, Hung-Chin Tsai, Ning-Chi Wang, Tung-Che Hung, Shu-Hsing Cheng, Chien-Ching Hung. Real-world effectiveness of direct-acting antivirals in people living with human immunodeficiency virus and hepatitis C virus genotype 6 infectionsWorld Journal of Gastroenterology 2022; 28(11): 1172-1183 doi: 10.3748/wjg.v28.i11.1172
21
Cecilia M. Shikuma, Thuy Le, Thao Vu Phuong, Glen M. Chew, Van Vinh Chau Nguyen, Trieu Ly Vo, Chathura Siriwardhana, Dominic Chow, Hayk Ghukasyan, Nath Limpruttidham, Thomas Premeaux, Louie Mar Gangcuangco, Robert Paul, Lishomwa C. Ndhlovu. Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in VietnamAIDS Research and Human Retroviruses 2022; 38(6): 441 doi: 10.1089/aid.2021.0076
22
Mohit Bhatia, Ekta Gupta. Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literatureJournal of Family Medicine and Primary Care 2020; 9(2): 531 doi: 10.4103/jfmpc.jfmpc_943_19
23
Saba Farooq, Sirmast Faiz, Atia-tul Wahab, M. Iqbal Choudhary. Determination of hepatitis C virus subtype prevalent in Sindh, Pakistan: a phylogenetic analysisScientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59342-7
24
Narayana Murthy Ganta, Gangaraju Gedda, Bethi Rathnakar, Mavurapu Satyanarayana, Bhaskar Yamajala, Mohamed Jawed Ahsan, Surender Singh Jadav, Tuniki Balaraju. A review on HCV inhibitors: Significance of non-structural polyproteinsEuropean Journal of Medicinal Chemistry 2019; 164: 576 doi: 10.1016/j.ejmech.2018.12.045